Contact

Email

l.kostos@unimelb.edu.au

Credentials

Position
Clinical (Lecturer)
The Sir Peter MacCallum Department of Oncology

Dr Louise Kostos

Clinical (Lecturer)
The Sir Peter MacCallum Department of Oncology
27 Scholarly works
0 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial
    DOI: 10.1016/j.euf.2026.05.017
  • 2025

    Journal article

    Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
    DOI: 10.2967/jnumed.125.270804
  • 2025

    Journal article

    Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
    DOI: 10.1016/S1470-2045(25)00559-5
  • 2025

    Conference Proceedings

    2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial
    DOI: 10.1016/j.annonc.2025.08.3002
  • 2025

    Journal article

    Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer
    DOI: 10.1111/bju.16751
  • 2025

    Journal article

    First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
    DOI: 10.1016/S1470-2045(25)00332-8
  • 2025

    Journal article

    Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
    DOI: 10.2967/jnumed.124.268640
Louise Kostos

RECENT SCHOLARLY WORKS

  • 2025

    Journal article

    Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
    DOI: 10.2967/jnumed.124.269252
  • 2025

    Journal article

    Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer
    DOI: 10.1016/j.eururo.2025.01.010
  • 2025

    Journal article

    Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617
    DOI: 10.1016/j.eururo.2025.08.015